Serum Indoleamine 2,3-Dioxygenase Activity Predicts Prognosis of Pulmonary Tuberculosis
Open Access
- 4 January 2012
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 19 (3), 436-442
- https://doi.org/10.1128/cvi.05402-11
Abstract
Tuberculosis (TB) continues to be a major health problem, and there are few biomarkers for predicting prognosis. Indoleamine 2,3-dioxygenase (IDO), a potent immunoregulatory molecule, catalyzes the rate-limiting step of tryptophan (Trp) degradation in the kynurenine (Kyn) pathway. An increase in IDO activity determined by the serum Trp/Kyn ratio has been shown to be associated with poor prognosis in cancers and bacteremia. In TB, however, there are no studies measuring serum IDO activity to determine its clinical significance. We evaluated serum IDO activity with 174 pulmonary TB (PTB) patients and 85 controls, using liquid chromatography/electrospray ionization tandem mass spectrometry. IDO activity was estimated by calculating the serum Kyn-to-Trp ratio. PTB patients had significantly higher Kyn concentrations and IDO activity and significantly lower Trp concentrations (P< 0.0001,P< 0.0001, andP< 0.0001, respectively) than the controls. Of 174 PTB patients, 39 (22.4%) died. The patients who died had significantly higher concentrations of Kyn and significantly lower Trp concentrations, resulting in significantly higher IDO activity (P< 0.0001,P< 0.0001, andP< 0.0001, respectively). In a receiver operating characteristic (ROC) analysis, serum IDO activity had the highest area under the curve (0.850), and this activity was an independent prognostic factor in multivariate analysis. These results suggest that serum IDO activity can be used as a novel prognostic marker in PTB.Keywords
This publication has 24 references indexed in Scilit:
- Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type ImmunityThe Journal of Immunology, 2009
- Biomarkers for tuberculosis disease activity, cure, and relapseThe Lancet Infectious Diseases, 2009
- Blockade of Indoleamine 2,3-Dioxygenase Protects Mice against Lipopolysaccharide-Induced Endotoxin ShockPublished by The American Association of Immunologists ,2009
- Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the hostMicrobes and Infection, 2009
- Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escapeImmunological Reviews, 2008
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJCI Insight, 2007
- Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma PatientsDermatology, 2006
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- Monitoring tryptophan metabolism in chronic immune activationClinica Chimica Acta; International Journal of Clinical Chemistry, 2006
- A Crucial Role for Tryptophan Catabolism at the Host/Candida albicansInterfaceThe Journal of Immunology, 2005